A study led by researchers from the Clínic-IDIBAPS paves the way for the design and optimization of CAR T-cell therapy for greater effectiveness in t1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
The University of Pennsylvania professor and pioneer in developing cancer therapies using T cells covered the history, current state, and future chal1
The researchers’ goal is to develop a method to reverse the exhaustion that affects T-cells during protracted battles with tumor cells, preventing th1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
The latest advance in the field of immune therapies against cancer are the active and targeted CAR therapies. This treatment consists of obtaining th1
